5q SMA can be grouped into four main ‘Types’. These are used by doctors at the time of diagnosis. They describe the age that symptoms start to show and the motor milestones (e.g. the ability to sit, stand and walk) that a child or adult would be expected to achieve.

*Adapted from Finkel et al., 2017¹

However, how severe and what impact SMA has varies from person to person, both within and between ‘Types’. Each child or adult is affected differently. Importantly, new drug treatments and better care and management are changing outcomes.

There is no cure for SMA and until late 2019 there were no NHS-approved drug treatments specifically for SMA in the UK.

There are now three NHS-funded, disease-modifying drug treatments:

• Spinraza™ / Nusinersen >
• Zolgensma™ / Onasemnogene >
• Evrysdi™/ Risdiplam >

These treatments are not suitable for everyone who has 5q SMA, but most people who have SMA Type 1, 2 or 3 can receive one of them.

These drugs can change what motor milestones babies and children may be able to achieve and improve their general health. The treatments work best if started before there is any muscle weakness, or when this is minimal. It is therefore important for treatment to be started as soon as possible². This is why clinicians and patient groups are calling for the earliest possible introduction of newborn screening for SMA in the UK.

Drug treatment is also important for adults living with SMA. Stabilising the condition later in life can make a huge difference – for example, preventing the loss of the ability to use a finger to control a powerchair or laptop.

​Whatever the outcome, any of these drug treatments must be combined with the best supportive care and management of symptoms. Information, such as how someone’s breathing ability is affected by their SMA and whether they are able to sit, stand or walk, is very important when it comes to making decisions about a drug treatment. This was why in 2017, the ‘International Standards of Care for SMA’ (SoC)^3,4,5 used the following broad categories to outline best care and support based on whether a child, young person or adult can be described as:

Though these guidelines are still important, they were written before the new drug treatments became more widely available. Nationally and internationally, clinicians, researchers and people living with SMA are working together to review and update these guidelines and keep up with the positive changes resulting from SMA therapies. Patient groups and clinicians in the UK want to see this work taking place here.

• The SMN1 gene²

5q SMA affects the nerve cells called lower motor neurons.

Lower motor neurons are found within the spinal cord. They receive electrical signals from the brain and carry these to the muscles. These respond leading to movement – such as crawling and walking. In the same way the lower motor neurons provide signals to the muscles we use for breathing and swallowing.

For these nerve cells to be healthy, our Survival Motor Neuron 1 (SMN1) genes⁶ must produce enough Survival Motor Neuron (SMN) protein.

Most people have two copies of the SMN1 gene. People with 5q SMA have two altered copies of the SMN1 gene. This means they are unable to produce enough functional (working) SMN protein to have healthy lower motor neurons⁷. As a result, the lower motor neuron cells in the spinal cord deteriorate. This means signals cannot easily get from the brain to the muscles making movement difficult. The muscles then waste due to lack of use – this is known as muscular atrophy.

In summary:

• The SMN2 gene²

A second gene also has a role in producing SMN protein. This is the Survival Motor Neuron 2 gene (SMN2), sometimes referred to as the SMA ‘back-up’ gene.

However, it is estimated that only about 10% of the SMN protein made from SMN2 is able to work properly. The large majority – about 90% – of protein produced from SMN2 is lacking an essential part meaning that it does not work⁸.

So, while SMN2 can make some functional SMN protein, it cannot produce enough to fully make up for the altered SMN1 gene in people who have 5q SMA.

Unlike most genes, the number of copies of SMN2 on each chromosome can vary from one person to the next⁹; there can be between 0 – 8 copies.

If you look across the whole population of people who have 5q SMA, the severity of SMA is linked to how much SMN protein is made^9,10. This means there is a general relationship between the number of SMN2 copies (‘SMN2 copy number’) and the likely severity of SMA symptoms^9,10. Having more SMN2 copies is generally associated with less severe SMA symptoms. However, at an individual level, a person’s SMN2 copy number on its own does not give an accurate prediction about the Type or severity of their SMA^3,4. This is likely to be because other genetic, and possibly environmental, factors have an influence on the condition.

Bearing this in mind, the following table gives a summary of:

• how many SMN2 copies the majority of people with each Type of SMA may have (see ‘usual number’ column), and
• the possible range of copy numbers that people with each Type of SMA may have (see ‘range’ column)

Table adapted from Tillmann et al. 2018¹¹

Any child or adult with suspected SMA will be physically examined. This may be by their GP, paediatrician or neurologist, who will ask about their medical history and concerns.

A GP may have met few, or even no children or adults who have SMA, so should make an immediate referral to a Regional (Specialist) Neuromuscular Centre.

If SMA is suspected, a blood sample for DNA (genetic) testing will be arranged. The sample is tested for a ‘deletion mutation’ in the Survival Motor Neuron 1 (SMN1) gene on chromosome 5. The number of SMN2 copies should also be assessed^3,4 as this can be a helpful indicator of what impact the condition may have.

Entry criteria for clinical trials and new drug treatments often say what number of SMN2 copies someone must have to take part.

The result of the SMN1 deletion test is usually available within 2 weeks though in some circumstances this may take longer. If there is any uncertainty about the diagnosis, further tests, such as an electromyogram (EMG) to record the electrical activity of muscles, may be discussed, but this is not usually needed to confirm 5q SMA.

5q SMA is passed from parents to their children through altered SMN1 genes. It usually follows an autosomal, recessive pattern of inheritance. This means that:

When two SMA carriers have a child together, for each pregnancy there is a:

• 1 in 4 (25%) chance that the child will inherit both altered copies of the SMN1 gene and will have SMA.
• 2 in 4 (50%) chance that the child will inherit one altered copy and one healthy copy of the SMN1 gene and will be a carrier.
• 1 in 4 (25%) chance that the child will inherit two healthy copies of the SMN1 gene and will not be a carrier or have SMA.

• An estimated 1 in 40 people carry the altered SMN1 gene¹².

This means that although SMA is a rare condition, around 1.69 million people^14-16 in the UK are carriers of the altered SMN1 gene.

• Every 5 days in the UK, a baby is born with SMA.

This is the incidence of SMA – the number of new cases of SMA at any one time.

Global studies suggest that 5q SMA affects an estimated 1 in 10,000 births. For every 100 SMA cases, approximately 60 babies would have the most severe SMA Type 1 (60%)^12,13.

In the UK in 2022, there were 676,275 live births^17-19. This suggests that approximately 68 babies were born who will develop a Type of 5q SMA. About 41 babies (60%) would have the more severe SMA Type 1.

• Global studies suggest that worldwide, between 1 and 2 people in every 100,000 have a Type of 5q SMA^12,13.

This is the prevalence – how many people are living with SMA in a population at any one time.

In mid-2022, the UK population was approximately 67.6 million^14-16. The global studies therefore suggest that between 675 and 1,350 people have SMA in the UK at any one time. There is no central information source, so the exact number is unknown.

However, these global studies were published before drug treatments became available. These treatments have had a life-saving impact for many children who have SMA Type 1 and have led to life-changing, healthier lives for many others. It therefore seems reasonable to suggest that the SMA prevalent population will slowly increase year by year.

There is still a considerable amount of research into SMA taking place around the world, and there are more drugs being tested in clinical trials. This will continue to improve our understanding of SMA and the effects of, and responses people have to, the current treatments. It will also help with the further development of effective management and care.

To keep up-to-date with the latest developments in research and drug treatments, see Treatments and Research.

1. Finkel RS Finkel RS et al. (2017) ENMC SMA Workshop Study Group. 218th ENMC International Workshop: Revisiting the consensus on standards of care in SMA Naarden, The Netherlands, 19-21 February 2016. Neuromuscul Disord 27: 596-605.

2. Dangouloff T & Servais L (2019) Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther Clin Risk Manag 15: 1153-1161.

3. A Guide to the 2017 International Standards of Care for SMA. Available at: smauk.org.uk/09nn (Last accessed: 25th July 2022).

4. Mercuri E et al. (2018) Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord 28: 103-115.

5. Finkel RS et al. (2018) Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord 28: 197-207.

6. Lefebvre S et al. (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80: 155-165.

7. Lunn MR & Wang CH (2008) Spinal muscular atrophy. Lancet 371: 2120-2133.

8. Ruggiu M et al. (2012) A role for SMN exon 7 splicing in the selective vulnerability of motor neurons in spinal muscular atrophy. Mol Cell Biol 32: 126-138.

9. Mailman MD et al. (2002). Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 4: 20-26.

10. Lefebvre S et al. (1997). Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 16: 265-269.

11. Tillmann R et al. (2018) Spinal Muscular Atrophy (SMA) type 1, a changing phenotype: implications for motor function and physiotherapy management from the Nusinersen Expanded Access Program (EAP). APCP Journal 9: 4-12.

12. Verhaart IEC et al. (2017) Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review. Orphanet J Rare Dis 12: 124.

13. Verhaart IEC, et al. (2017) A multi-source approach to determine SMA incidence and research ready population. J Neurol 264: 1465-1473.

14. Office for National Statistics (November 2022) Population of England and Wales: tinyurl.com/ykftm77n (last accessed 27th November 2023)

15. Scotland’s Census 2022 – Rounded Population Estimates: tinyurl.com/2bfw635h (last accessed 27th November 2023)

16. 2022 Mid-Year population Estimates for Northern Ireland tinyurl.com/mpphmswh (last accessed 27th November 2023)

17. Office of National Statistics (2021) Births in England and Wales: 2020. Available at: tinyurl.com/3ky86caf (last accessed 13th November 2023)

18. Annual births, deaths, marriages and other vital events. Vital Events Reference Tables 2022. Section 3 Births. Published on 20th July 2023: tinyurl.com/4shymnbj (last accessed 13th November 2023)

19. Northern Ireland Statistics and Research Agency Registrar General Annual Report 2022 Births. Published: 26th October 2023. tinyurl.com/yc7j3msb (last accessed 13th November 2023)